Tocilizumab may improve survival in sickest COVID-19 patients, scientists say

Among other treatments, they said tocilizumab was considered for off-label usage for the patients whose respiratory symptoms were declining -- many of whom were requiring mechanical ventilator support. In the observational study, the researchers noted that 210 patients received tocilizumab, and the other 420 did not.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/31eU9Oi
via IFTTT